<DOC>
	<DOCNO>NCT00639002</DOCNO>
	<brief_summary>The purpose study determine clinical efficacy safety ruxolitinib ( INCB018424 ) , small molecule Janus kinase 2 ( JAK2 ) -inhibitor , patient refractory relapse multiple myeloma .</brief_summary>
	<brief_title>A Study Determine Effect Safety Oral Janus Kinase 2 ( JAK2 ) -Inhibitor ( Ruxolitinib ; INBC018424 ) Patients With Multiple Myeloma</brief_title>
	<detailed_description>The protocol originally design Simon two stage determine initial 13 patient enrolled meet definition 'responder ' accord International Uniform Response Criteria multiple myeloma protocol amend allow patient disease progression time stable disease 3 cycle meet withdrawal criterion withdrawn consent 40 mg dexamethasone add dose ruxolitinib .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma evidence measurable disease . Relapsed refractory disease least one line prior therapy . Adequate bone marrow reserve . Received anticancer medication investigational therapy past 28 day . Intracranial disease epidural disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>